Bariatric Surgery May Resolve Liver Disease Science Daily (press release) - The pathophysiologic mechanisms of NAFLD have not been clearly elucidated as yet, but obesity and insulin resistance are considered to be the main causative ...
Slumber the Pounds Away KUNC, CO - Insensitivity to insulin is a precursor to type II diabetes. The hormone itself promotes weight gain, another diabetes risk factor. ...
Diamyd Medical: Diamyd? Diabetes Vaccine - Three Blockbuster ... Business Wire (press release), CA - As reported in New England Journal of Medicine (Oct 30, 2008), Diamyd? preserves insulin producing beta cells best in patients recently diagnosed with the ...
They may be big, but are football linemen healthy? Los Angeles Times, CA - Nov 26, 2008 Some of those risk factors include having extra abdominal fat, high blood pressure, elevated levels of "bad" cholesterol and insulin resistance. ...
More exercise, rest cut risk in women Boston Globe, United States - Nov 23, 2008 "Exercise may reduce cancer risk by improving immunity, regulating insulin and glucose levels, and by maintaining normal sex hormone levels," said McClain. ...
Source: Google News
Recent News and Articles on the Keywords: insulin + 697 + 0.18 Related to the article below (Last Update: 8/7/2008)
Gerresheimer Wilden: Czech insulin pens plant opens Plasteurope, Germany - ... www.gerresheimer.de), has opened a new production hall for insulin pens for the treatment of diabetes at its Horsovsk? T?n / Czech Republic facility. ...FRA:GXI
Associations of Adiponectin, Resistin, and Tumor Necrosis Factor ... Journal of Clinical Endocrinology and Metabolism, MD - Context: Adipose tissue-derived adipokines may contribute to insulin resistance. Objective: We tested the hypothesis that adipokines are associated with ...
Medication Helps Some Diabetics Live Insulin-Free RedOrbit, TX - Aug 6, 2008 Colvin took insulin injections twice a day, but as a child, decided to administer them himself. "I'm a big St. Louis Cardinals fan and my dad is a huge ...
[PDF]Prevalence and incidence of non-insulin-dependent diabetes - SJ Kenny, RE Aubert, LS Geiss - Diabetes in America, 1995 - hawaii.edu ... Chapter 4 Prevalence and Incidence of Non-Insulin-Dependent Diabetes SUMMARY Susan
J. Kenny, PhD; Ronald E. Aubert, PhD; and Linda S. Geiss, MA ...
Independent stimulation of glucose metabolism and Na+-K+ exchange by insulin in the human forearm - E Ferrannini, S Taddei, D Santoro, A Natali, C … - American Journal of Physiology- Endocrinology And Metabolism, 1988 - Am Physiological Soc ... of 0.5 mM) was superimposed on the insulin infusion, potas- sium uptake was blocked
(0.026 t ... 30% fall in forearm blood flow (from 2.95 t 0.10 to 2.01 t 0.18 ml ...
Inhaled insulin has some lung risk; Diabetics eager to try Pfizer product that may decrease or eliminate need for
injections.
NEW YORK -- After more than two decades of daily needle injections to treat his diabetes, Ken Wagner says he is eager to try Exubera, the first inhaled insulin that drugmaker Pfizer Inc. started promoting to doctors Monday.
For seven years Wagner, 41, has had a needle-like plastic tube inserted into his skin carrying life-sustaining insulin into his bloodstream as needed from a pager-sized portable pump. Before that, Wagner gave himself injections four times a day.
"We are all just waiting to be totally relieved of this problem," says Wagner, a bank compliance officer who lives in New York City and has had diabetes since he was 15. Though Exubera studies show it can damage the lungs of a small portion of users, Wagner says, "I'll take the potential negatives of an inhaled device over the insulin pump."
Pfizer will unleash 2,300 salespeople in the United States to promote to doctors the water bottle- shaped inhaler that can reduce the need for insulin shots in some patients and eliminate it in others. The product will be available for patients in September, seven months after being approved by U.S. regulators.
Pfizer, the world's largest drugmaker, spent more than 10 years perfecting the product and tested it in 3,500 patients over seven years, says Michael Berelowitz, Pfizer vice president for worldwide medical research, who helped develop the product.
The inhaled insulin has been anticipated by many patients, said Christopher Saudek, a professor at Johns Hopkins University School of Medicine in Baltimore and past president of the American Diabetes Association.
"There is a lot of excitement about trying it out. The main attraction is that it frees you from some needle sticks. It's the beginning of an era where we will be able to deliver insulin by the inhaled route, through the lungs."
